4/27/2012

The FDA approved Novartis' Afinitor, or everolimus, to treat renal angiomyolipomas in patients with tuberous sclerosis complex. The drug previously was approved for patients with advanced renal cell cancer who failed to respond to treatment with Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals' Nexavar or Pfizer's Sutent.

Related Summaries